Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02286804 · ClinicalTrials.gov registry record · NA
Ultherapy for the Treatment of Spider Veins on the Legs
A NA study of Telangiectasia and Spider Veins, sponsored by Ulthera.
- Completed
- Registry status
- NA
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT02286804: Completed NA study of Telangiectasia and Spider Veins, sponsored by Ulthera.
NCT02286804 is a NA study of Telangiectasia and Spider Veins that has completed, run by Ulthera. The registered enrollment target is 9 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02286804, a NA study of Telangiectasia and Spider Veins, has completed, sponsored by Ulthera.
- COMPLETED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
Up to 30 enrolled subjects will be treated. Enrolled subjects will receive Ultherapy® treatments along each length of the spider vein. Follow-up visits will occur at 30 and 60 days post-treatment. Study images will be obtained pre-treatment, immediately post-treatment, and at each follow-up visit.
Primary Outcome
Determined by a masked, qualitative assessment of 2D photographs compared to baseline, based on level of clearance/improvement. Level of improvement scale: * 0 = 0% Improvement (None) * 1 = \< 25% Improvement (Mild) * 2 = 26 to 50% Improvement (Moderate) * 3 = 51 to 75% Improvement (Significant) * 4 = 76 to 100% Improvement (Very Significant)
Conditions Studied
Interventions
- DEVICE Ultherapy
Study Locations (1)
Arizona
- Ulthera, Inc. - Mesa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2014-10 |
| Est. Completion | 2015-05 |
| Phase | NA |
What the finished NCT02286804 record still lists
NCT02286804 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Telangiectasia appearing as the primary indexed condition, and to 1 intervention - of which Ultherapy is the first listed.
NCT02286804 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT02286804 about?
NCT02286804 is a clinical study titled "Ultherapy for the Treatment of Spider Veins on the Legs". Up to 30 enrolled subjects will be treated. Enrolled subjects will receive Ultherapy® treatments along each length of the spider vein. Follow-up visits will occur at 30 and 60 days post-treatment. Study images will be obtained pre-treatment, immediately post-treatment, and at each follow-up visit.
What is the current status of trial NCT02286804?
This trial is currently completed. It is a NA study. The enrollment target is 9 participants. The study started on 2014-10. Estimated completion is 2015-05.
What conditions does trial NCT02286804 study?
This clinical trial studies the following conditions: Telangiectasia, Spider Veins.
What interventions are being tested in trial NCT02286804?
The interventions under investigation include: Ultherapy (DEVICE).
Who is sponsoring clinical trial NCT02286804?
This trial is sponsored by Ulthera, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02286804 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Telangiectasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02286804's enrollment target sits among peer trials
9 1975th of 2000 higher than 25 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia